 |
|
Preventing toxic side effects of inflammatory disease therapy
February 09, 2006Researchers at the University of California, San Diego (UCSD) School of Medicine have developed a mouse model that could help scientists develop better drugs to fight autoimmune and inflammatory disorders such as multiple sclerosis and rheumatoid arthritis.
Inflammation is a process by which the white blood cells and chemicals of the immune system rally to protect the body from infection and foreign substances such as bacteria and viruses. In autoimmune diseases, however, this defense system triggers an inflammatory response when there are no foreign substances to fight off, or the defense system goes into "overdrive" and forgets how to turn off. In these diseases, the body's normally protective immune system attacks and damages its own healthy tissues.
UCSD researcher Mark H. Ginsberg, M.D., professor of Medicine at the University of California, San Diego (UCSD) School of Medicine, and his colleagues have identified a mechanism to selectively disrupt signaling to recruit lymphocytes and monocytes - white blood cells sent to sites of inflammation to fight infection - while maintaining the body's other essential immune system functions. Their findings appear online on February 9 in advance of print publication in the March issue of the Journal of Clinical Investigation.
In the case of certain autoimmune diseases, the alpha 4 integrins cause white blood cells to accumulate at the site of the disease, resulting in inflammation. An integrin is a surface molecule found on the exterior of cells that helps cells adhere and migrate. It is also believed to be responsible for a role in cell signaling, which allows cells to communicate with the extracellular environment. One of the promising treatments for disorders such as multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis - the alpha 4 integrin antagonist - works by blocking cell adhesion. However, this anti-inflammatory therapy could cause adverse side effects, such as impairment of the immune system and the patient's ability to develop new red and white blood cells in the bone marrow, a process called hematopoiesis.
"Our goal was to identify a more specific target of alpha 4 integrin molecules in order to interfere with their roles in disease progression while sparing alpha4 functions required for normal health," said David M. Rose, D.V.M., Ph.D., assistant professor of medicine at UCSD, and co-author of the study.
The research team created mutant mice known as "alpha4(Y991A) mice," in which the alpha4 integrin can no longer bind to a signaling protein inside the cell called paxillin. Previously generated alpha4 integrin deficient mutant mice died at birth because too many aspects of alpha4 function were changed. The new alpha4(Y991A) mice have an impairment only in the interaction between alpha4 and paxillin, and thus have fewer effects on development. The researchers discovered that, in contrast to normal mice, alpha4(Y991A) mice exposed to an inflammatory stimulus recruited fewer circulating white blood cells (B and T cells) to the region of exposure. However, the development of new B and T cells was unaffected.
The authors suggest that these mice are a valuable tool to test models of inflammatory and autoimmune diseases of humans, and that a new class of pharmaceutical agents that target the specific interaction of paxillin and alpha4 integrin could be important future treatments of inflammatory disease.
"We were surprised to find that the mutation actually had very little effect on the animal's development of lymphocytes, the white blood cells that fight infection," said Rose. "This could prove to be an important first step in development of a more effective drug to target alpha4 integrins in autoimmune and inflammatory disease of humans."
Additional co-authors include Kenneth Kaushansky, M.D., Chloé C. Féral, Jaewon Han, Norman Fox and Gregg J. Silverman, UCSD Department of Medicine.
University of California-San Diego
In the case of certain autoimmune diseases, the alpha 4 integrins cause white blood cells to accumulate at the site of the disease, resulting in inflammation. An integrin is a surface molecule found on the exterior of cells that helps cells adhere and migrate. It is also believed to be responsible for a role in cell signaling, which allows cells to communicate with the extracellular environment. One of the promising treatments for disorders such as multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis - the alpha 4 integrin antagonist - works by blocking cell adhesion. However, this anti-inflammatory therapy could cause adverse side effects, such as impairment of the immune system and the patient's ability to develop new red and white blood cells in the bone marrow, a process called hematopoiesis.
"Our goal was to identify a more specific target of alpha 4 integrin molecules in order to interfere with their roles in disease progression while sparing alpha4 functions required for normal health," said David M. Rose, D.V.M., Ph.D., assistant professor of medicine at UCSD, and co-author of the study.
The research team created mutant mice known as "alpha4(Y991A) mice," in which the alpha4 integrin can no longer bind to a signaling protein inside the cell called paxillin. Previously generated alpha4 integrin deficient mutant mice died at birth because too many aspects of alpha4 function were changed. The new alpha4(Y991A) mice have an impairment only in the interaction between alpha4 and paxillin, and thus have fewer effects on development. The researchers discovered that, in contrast to normal mice, alpha4(Y991A) mice exposed to an inflammatory stimulus recruited fewer circulating white blood cells (B and T cells) to the region of exposure. However, the development of new B and T cells was unaffected.
The authors suggest that these mice are a valuable tool to test models of inflammatory and autoimmune diseases of humans, and that a new class of pharmaceutical agents that target the specific interaction of paxillin and alpha4 integrin could be important future treatments of inflammatory disease.
"We were surprised to find that the mutation actually had very little effect on the animal's development of lymphocytes, the white blood cells that fight infection," said Rose. "This could prove to be an important first step in development of a more effective drug to target alpha4 integrins in autoimmune and inflammatory disease of humans."
Additional co-authors include Kenneth Kaushansky, M.D., Chloé C. Féral, Jaewon Han, Norman Fox and Gregg J. Silverman, UCSD Department of Medicine.
University of California-San Diego
More Inflammatory Disease Therapy Current Events and Inflammatory Disease Therapy News Articles
 |
Medical Management of Diabetes Mellitus (Inflammatory Disease and Therapy) by Nathaniel G. Clark (Author), William T. Cefalu (Author), Jack L. Leahy (Author) Univ. of Vermont, Burlington. 'How-to' manual outlining the most effective diagnostic and therapeutic approaches to clinical problems in diabetes. Discusses signs and symptoms, therapies, complications, special clinical settings, standards of care, and more. For clinicians and students. |
 |
Behcet's Disease (Inflammatory Disease and Therapy) by Desmond Oduffy (Editor) Ninety-three papers presented at the Fifth International Conference on Behcets' Disease held at the Mayo Clinic in Rochester, Minnesota, September 1989, are organized within four sections: diagnostic criteria and epidemiology; clinical manifestations ocular,, neurological, vascular and pulmonary, cu |
 |
Monoclonal Antibodies, Cytokines and Arthritis (Inflammatory Disease and Therapy) by Kresina (Author) Presents a sampling of new and novel approaches to the amelioration of musculoskeletal disease pathology, emphasizing prevention and therapy. Where applicable, these new technologies are focused on their application to human autoimmune diseases, but the volume mainly discusses and details the use of |
|
Platelet-Activating Factor in Endotoxin and Immune Diseases (Inflammatory Disease and Therapy) by Dean A. Handley (Contributor) | |
|
Inflammatory Disease Therapy: Preclinical and Clinical Developments (Agents and Actions Supplements) by R. J. Booney (Author), Niall S. Doherty (Author), D. W. Morgan (Author), A. F. Welton (Editor) | |
|
Immunomodulators in the Rheumatic Diseases (Inflammatory Disease and Therapy) by Daniel E. Furst (Author), Michael E. Weinblatt (Editor) | |
 |
Second-line Agents in the Treatment of Rheumatic Diseases (Inflammatory Disease and Therapy) by J. S. Dixon (Author) Examining the use of second-line agents or disease-modifying antirheumatic drugs to treat a wide range of arthropathies, this practical reference reviews the clinical efficacy, recognized side effects, optimal use, mechanisms of action and clinical pharmacology of these important compounds. |
|
Methotrexate Therapy in Rheumatic Disease (Inflammatory Disease and Therapy) by William S. Wilke (Editor) | |
 |
Acute Rheumatic and Immunological Diseases: Management of the Critically Ill Patient (Inflammatory Disease and Therapy) by B. F. Mandell (Author) Presenting an overview of the specific clinical problems that may be secondary to underlying immunological processes, this comprehensive reference details practical approaches for diagnosing and treating critically ill patients with rheumatic or immunological diseases. Emphasizing the clinical utililty of the procedures discussed, Acute Rheumatic and Immunological Diseases includes useful algorithms to sort through interrelated medical conditions and diagnoses focuses on acute management issues rather than on chronic therapy for rheumatic and immunological diseases provides an exhaustive review of drug overdosage and toxicity delineates successful treatment strategies for hematological, cardiopulmonary, and renal problems analyzes specific therapeutic modalities and much more! |
 |
Joint Cartilage Degradation (Inflammatory Disease and Therapy) by Jr. (Author) This broadly-based reference covers all aspects of both the normal and pathological degradation of the cartilage matrix - from basic descriptions of cartilage structure to potential treatments that promote repair or regeneration of damaged cartilage.;Focusing on cartilage of the articular surfaces, this book presents all of the relevant biochemical background material; discusses in detail the building blocks of cartilage, such as collagen, aggrecan, glycoproteins and proteinases; considers both the biochemical and mechanical characteristics of cartilage breakdown; analyzes the whole organism, tissue culture and cell culture; and reviews regulatory factors, including hormones, growth factors, interleukins and retinoids. |
| © 2009 BrightSurf.com |